HEFTME System for Adjuvant Therapeutic Selection of Locally Advanced UTUC Postoperatively：A Perspective Cohort Study

Launched by PEKING UNIVERSITY FIRST HOSPITAL · Jan 22, 2025

Keywords

ClinConnect Summary

The HEFTME clinical trial is studying a new system designed to help doctors predict how well patients with a specific type of cancer, called Upper Tract Urothelial Carcinoma (UTUC), might respond to treatment after surgery. This system uses a special staining technique on tissue samples to better understand the tumor's environment and guide doctors in choosing the most suitable follow-up treatments for patients who have more advanced stages of the disease, specifically those with muscle invasion or lymph node spread.

To participate in this study, patients need to have a confirmed diagnosis of UTUC that is more serious than early stages, meaning it has invaded deeper tissues or spread to lymph nodes. Unfortunately, those with early-stage disease or incomplete medical information won't be included. While the study is not yet recruiting participants, those who are eligible can expect to contribute to important research that may improve treatment options for future patients with this cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • pathological diagnose of UTUC;
• • Met more than muscle-invasion stages(pT2+) or lymph nodes metastasis.
• Exclusion Criteria:
• • Patients with early-local stages (pTa/T1/Tis) without LNM+ and those with incomplete pathologic and prognostic information were excluded